Home > Dermatology > EADV 2022 > Activation of the A3 adenosine receptor: a new mode of action to treat psoriasis?

Activation of the A3 adenosine receptor: a new mode of action to treat psoriasis?

Presented By
Dr Kim A. Papp, Probity Medical Research, Canada
Conference
EADV 2022
Trial
Phase 3, COMFORT
Piclidenoson reached its primary endpoint with a statistical difference over placebo while showing a very good safety profile. However, the A3 adenosine receptor agonist did not outperform the active comparator apremilast. “I think we can all agree that despite the fact that we may have very effective treatments for any disease it’s always important to explore new targets and develop new therapies,” Dr Kim A. Papp (Probity Medical Research, Canada) said, referring to his point that no medication is universally effective for every patient [1]. The phase 3 COMFORT trial (NCT03168256) explored the small molecule piclidenoson, a selective A3 adenosine receptor agonist that only binds to inflammatory cells. The agent has the ability to inhibit IL-17 and IL-23 expression in keratinocytes. The study randomised 529 patients into 4 different treatment arms with a twi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on